Skip to content

4598.T

Delta-Fly Pharma,Inc.

グロース · 医薬品 · 医薬品 · JP

JPY 111.00
−9.02%
Ask drillr

Year over year

Reported trailing growth

Revenue
EBITDA
EBIT
+5.6%
EPS
+26.7%
Free cash flow
Operating cash flow

Forward estimates

Based on analyst estimates

Revenue
EBITDA
EPS
+4.0%

Three-year CAGR

Revenue
EBITDA
-21.8%
EBIT
-21.7%
Net income
-20.4%
EPS
+1.6%
Free cash flow
-43.3%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026